Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05847192 · ClinicalTrials.gov registry record
Tau Networks in Psychotic Alzheimer's Disease
A clinical trial of Alzheimer Disease and Alzheimer Disease With Delusions, sponsored by Northwell Health.
- Recruiting
- Registry status
- 91
- Enrollment target
- 1
- Study location
NCT05847192: Recruiting study of Alzheimer Disease and Alzheimer Disease With Delusions, sponsored by Northwell Health.
NCT05847192 is a study of Alzheimer Disease and Alzheimer Disease With Delusions that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 91 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05847192, a study of Alzheimer Disease and Alzheimer Disease With Delusions, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.
Primary Outcome
To measure the distribution of tau aggregation in AD patients with and without psychosis, compared to cognitively unimpaired healthy subjects with the PET radiotracer \[18F\]-PI2620.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST [18F]-PI2620 PET scan
Study Locations (1)
New York
- The Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2029-12-31 |
What NCT05847192 shows while recruiting
NCT05847192 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]-PI2620 PET scan is the first listed.
NCT05847192 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05847192 about?
NCT05847192 is a clinical study titled "Tau Networks in Psychotic Alzheimer's Disease". This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social co...
What is the current status of trial NCT05847192?
This trial is currently recruiting. The enrollment target is 91 participants. The study started on 2023-04-13. Estimated completion is 2029-12-31.
What conditions does trial NCT05847192 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis.
What interventions are being tested in trial NCT05847192?
The interventions under investigation include: [18F]-PI2620 PET scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05847192?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05847192 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05847192's enrollment target sits among peer trials
91 159th of 306 higher than 148 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI